JP2019529472A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019529472A5 JP2019529472A5 JP2019516442A JP2019516442A JP2019529472A5 JP 2019529472 A5 JP2019529472 A5 JP 2019529472A5 JP 2019516442 A JP2019516442 A JP 2019516442A JP 2019516442 A JP2019516442 A JP 2019516442A JP 2019529472 A5 JP2019529472 A5 JP 2019529472A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- compound according
- pharmaceutical composition
- compound
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 173
- 239000008194 pharmaceutical composition Substances 0.000 claims description 97
- 238000000034 method Methods 0.000 claims description 95
- 239000000203 mixture Substances 0.000 claims description 75
- 208000002193 Pain Diseases 0.000 claims description 40
- 230000036407 pain Effects 0.000 claims description 38
- 230000002757 inflammatory effect Effects 0.000 claims description 36
- 230000004968 inflammatory condition Effects 0.000 claims description 34
- 208000024827 Alzheimer disease Diseases 0.000 claims description 20
- 125000003118 aryl group Chemical group 0.000 claims description 20
- 125000005842 heteroatom Chemical group 0.000 claims description 16
- 125000006574 non-aromatic ring group Chemical group 0.000 claims description 16
- 230000001965 increasing effect Effects 0.000 claims description 15
- 102000013462 Interleukin-12 Human genes 0.000 claims description 14
- 108010065805 Interleukin-12 Proteins 0.000 claims description 14
- 125000001931 aliphatic group Chemical group 0.000 claims description 12
- 230000013629 beta-amyloid clearance Effects 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 12
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 102000004127 Cytokines Human genes 0.000 claims description 10
- 108090000695 Cytokines Proteins 0.000 claims description 10
- 102000003814 Interleukin-10 Human genes 0.000 claims description 10
- 108090000174 Interleukin-10 Proteins 0.000 claims description 10
- 102000004388 Interleukin-4 Human genes 0.000 claims description 10
- 108090000978 Interleukin-4 Proteins 0.000 claims description 10
- 230000036470 plasma concentration Effects 0.000 claims description 10
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 10
- 125000001118 alkylidene group Chemical group 0.000 claims description 9
- -1 1,2-methylenedioxy Chemical group 0.000 claims description 8
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical group C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 8
- 201000001119 neuropathy Diseases 0.000 claims description 8
- 230000007823 neuropathy Effects 0.000 claims description 8
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 8
- 125000004076 pyridyl group Chemical group 0.000 claims description 8
- 201000010374 Down Syndrome Diseases 0.000 claims description 7
- 206010044688 Trisomy 21 Diseases 0.000 claims description 7
- 208000010877 cognitive disease Diseases 0.000 claims description 7
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 6
- 201000001320 Atherosclerosis Diseases 0.000 claims description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 6
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 6
- 208000011231 Crohn disease Diseases 0.000 claims description 6
- 201000009273 Endometriosis Diseases 0.000 claims description 6
- 102000003816 Interleukin-13 Human genes 0.000 claims description 6
- 108090000176 Interleukin-13 Proteins 0.000 claims description 6
- 102000013691 Interleukin-17 Human genes 0.000 claims description 6
- 108050003558 Interleukin-17 Proteins 0.000 claims description 6
- 102000000704 Interleukin-7 Human genes 0.000 claims description 6
- 108010002586 Interleukin-7 Proteins 0.000 claims description 6
- 208000018737 Parkinson disease Diseases 0.000 claims description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 6
- 229910052794 bromium Inorganic materials 0.000 claims description 6
- 230000003920 cognitive function Effects 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 210000001320 hippocampus Anatomy 0.000 claims description 6
- 230000004410 intraocular pressure Effects 0.000 claims description 6
- 230000027928 long-term synaptic potentiation Effects 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 208000010412 Glaucoma Diseases 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 5
- 208000027418 Wounds and injury Diseases 0.000 claims description 5
- 208000014674 injury Diseases 0.000 claims description 5
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 5
- 230000009529 traumatic brain injury Effects 0.000 claims description 5
- 206010020751 Hypersensitivity Diseases 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
- 102000015696 Interleukins Human genes 0.000 claims description 4
- 108010063738 Interleukins Proteins 0.000 claims description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 4
- 208000030961 allergic reaction Diseases 0.000 claims description 4
- 230000001363 autoimmune Effects 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 230000000968 intestinal effect Effects 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 4
- 230000004770 neurodegeneration Effects 0.000 claims description 4
- 125000004043 oxo group Chemical group O=* 0.000 claims description 4
- 210000003200 peritoneal cavity Anatomy 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 230000000770 proinflammatory effect Effects 0.000 claims description 4
- 230000001185 psoriatic effect Effects 0.000 claims description 4
- 125000000464 thioxo group Chemical group S=* 0.000 claims description 4
- 230000000699 topical effect Effects 0.000 claims description 4
- 206010030043 Ocular hypertension Diseases 0.000 claims description 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 3
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 3
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 2
- 208000030507 AIDS Diseases 0.000 claims description 2
- 208000007848 Alcoholism Diseases 0.000 claims description 2
- 208000037259 Amyloid Plaque Diseases 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 208000000412 Avitaminosis Diseases 0.000 claims description 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 2
- 208000005171 Dysmenorrhea Diseases 0.000 claims description 2
- 208000001640 Fibromyalgia Diseases 0.000 claims description 2
- 208000005577 Gastroenteritis Diseases 0.000 claims description 2
- 201000005569 Gout Diseases 0.000 claims description 2
- 206010019233 Headaches Diseases 0.000 claims description 2
- 208000007514 Herpes zoster Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 206010021135 Hypovitaminosis Diseases 0.000 claims description 2
- 206010062016 Immunosuppression Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 208000012659 Joint disease Diseases 0.000 claims description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 2
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 2
- 201000002832 Lewy body dementia Diseases 0.000 claims description 2
- 208000000112 Myalgia Diseases 0.000 claims description 2
- 208000009525 Myocarditis Diseases 0.000 claims description 2
- 208000004983 Phantom Limb Diseases 0.000 claims description 2
- 206010056238 Phantom pain Diseases 0.000 claims description 2
- 208000004550 Postoperative Pain Diseases 0.000 claims description 2
- 206010045171 Tumour pain Diseases 0.000 claims description 2
- 208000035868 Vascular inflammations Diseases 0.000 claims description 2
- 238000009825 accumulation Methods 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 208000005298 acute pain Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- 230000009286 beneficial effect Effects 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 208000019069 chronic childhood arthritis Diseases 0.000 claims description 2
- 230000006999 cognitive decline Effects 0.000 claims description 2
- 210000002808 connective tissue Anatomy 0.000 claims description 2
- 230000001934 delay Effects 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000004064 dysfunction Effects 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 231100000869 headache Toxicity 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- 208000003532 hypothyroidism Diseases 0.000 claims description 2
- 230000002989 hypothyroidism Effects 0.000 claims description 2
- 230000001506 immunosuppresive effect Effects 0.000 claims description 2
- 239000012678 infectious agent Substances 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 238000007913 intrathecal administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 238000007914 intraventricular administration Methods 0.000 claims description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 208000013465 muscle pain Diseases 0.000 claims description 2
- 201000008383 nephritis Diseases 0.000 claims description 2
- 210000000653 nervous system Anatomy 0.000 claims description 2
- 230000000626 neurodegenerative effect Effects 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 210000002027 skeletal muscle Anatomy 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 230000003956 synaptic plasticity Effects 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 230000002485 urinary effect Effects 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 208000030401 vitamin deficiency disease Diseases 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 208000025747 Rheumatic disease Diseases 0.000 claims 1
- 102000019355 Synuclein Human genes 0.000 claims 1
- 108050006783 Synuclein Proteins 0.000 claims 1
- 229940047122 interleukins Drugs 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 230000000552 rheumatic effect Effects 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 0 *C[C@@](C(C1O)O)O[C@]1N(C=CC(N1Cc(cc2-c3ccccc3)ncc2F)=O)C1=O Chemical compound *C[C@@](C(C1O)O)O[C@]1N(C=CC(N1Cc(cc2-c3ccccc3)ncc2F)=O)C1=O 0.000 description 1
- TYIWPBWUTGRKGT-VWRAKTAISA-N Cc1c(CN(C(C=CN2CC(CO[C@@H]3CO)(C3O)O)=O)C2=O)nccc1-c1ccccc1 Chemical compound Cc1c(CN(C(C=CN2CC(CO[C@@H]3CO)(C3O)O)=O)C2=O)nccc1-c1ccccc1 TYIWPBWUTGRKGT-VWRAKTAISA-N 0.000 description 1
- AVKIFKMDHWOPPA-WYNBGMTASA-N Cc1cc(-c2ccccc2)cc(CN(C(C=CN2[C@@H](C3O)O[C@H](CO)C3O)=O)C2=O)n1 Chemical compound Cc1cc(-c2ccccc2)cc(CN(C(C=CN2[C@@H](C3O)O[C@H](CO)C3O)=O)C2=O)n1 AVKIFKMDHWOPPA-WYNBGMTASA-N 0.000 description 1
- LADNXXNDLAEQAA-WYNBGMTASA-N Cc1cnc(CN(C(C=CN2[C@@H](C3O)O[C@H](CO)C3O)=O)C2=O)cc1-c1ccccc1 Chemical compound Cc1cnc(CN(C(C=CN2[C@@H](C3O)O[C@H](CO)C3O)=O)C2=O)cc1-c1ccccc1 LADNXXNDLAEQAA-WYNBGMTASA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000001738 Nervous System Trauma Diseases 0.000 description 1
- OVVSVZWQPYOFSG-SGZDXZSOSA-N OC[C@H](C(C1O)O)O[C@H]1N(C=CC(N1Cc(nc2)cc(-c3ccccc3)c2Cl)=O)C1=O Chemical compound OC[C@H](C(C1O)O)O[C@H]1N(C=CC(N1Cc(nc2)cc(-c3ccccc3)c2Cl)=O)C1=O OVVSVZWQPYOFSG-SGZDXZSOSA-N 0.000 description 1
- RNZYZIJVYCNWMP-BTWUCOSQSA-N OC[C@H](C(C1O)O)O[C@H]1N(C=CC(N1Cc(nccc2-c3ccccc3)c2Cl)=O)C1=O Chemical compound OC[C@H](C(C1O)O)O[C@H]1N(C=CC(N1Cc(nccc2-c3ccccc3)c2Cl)=O)C1=O RNZYZIJVYCNWMP-BTWUCOSQSA-N 0.000 description 1
- BIVFCCSHYQXVJV-BTWUCOSQSA-N OC[C@H](C(C1O)O)O[C@H]1N(C=CC(N1Cc2nc(C(F)(F)F)cc(-c3ccccc3)c2)=O)C1=O Chemical compound OC[C@H](C(C1O)O)O[C@H]1N(C=CC(N1Cc2nc(C(F)(F)F)cc(-c3ccccc3)c2)=O)C1=O BIVFCCSHYQXVJV-BTWUCOSQSA-N 0.000 description 1
- GNBVVAPNOLAERL-BTWUCOSQSA-N OC[C@H](C(C1O)O)O[C@H]1N(C=CC(N1Cc2nccc(-c3ccccc3)c2C(F)(F)F)=O)C1=O Chemical compound OC[C@H](C(C1O)O)O[C@H]1N(C=CC(N1Cc2nccc(-c3ccccc3)c2C(F)(F)F)=O)C1=O GNBVVAPNOLAERL-BTWUCOSQSA-N 0.000 description 1
- ZQEKWMVTBSRIBS-FEPNQTLGSA-N OC[C@H](C1O)OCC1(CN(C=CC(N1Cc(nccc2-c3ccccc3)c2F)=O)C1=O)O Chemical compound OC[C@H](C1O)OCC1(CN(C=CC(N1Cc(nccc2-c3ccccc3)c2F)=O)C1=O)O ZQEKWMVTBSRIBS-FEPNQTLGSA-N 0.000 description 1
- QSVXHHJYMKZCAL-HOHBBMLPSA-N OC[C@H](C1O)OCC1(CN(C=CC(N1Cc2ncc(C(F)(F)F)c(-c3ccccc3)c2)=O)C1=O)O Chemical compound OC[C@H](C1O)OCC1(CN(C=CC(N1Cc2ncc(C(F)(F)F)c(-c3ccccc3)c2)=O)C1=O)O QSVXHHJYMKZCAL-HOHBBMLPSA-N 0.000 description 1
- 102000003802 alpha-Synuclein Human genes 0.000 description 1
- 108090000185 alpha-Synuclein Proteins 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 208000028412 nervous system injury Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662399691P | 2016-09-26 | 2016-09-26 | |
| US62/399,691 | 2016-09-26 | ||
| PCT/US2017/053565 WO2018058148A1 (en) | 2016-09-26 | 2017-09-26 | Uridine nucleoside derivatives, compositions and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019529472A JP2019529472A (ja) | 2019-10-17 |
| JP2019529472A5 true JP2019529472A5 (enExample) | 2020-11-12 |
| JP7121731B2 JP7121731B2 (ja) | 2022-08-18 |
Family
ID=61690038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019516442A Active JP7121731B2 (ja) | 2016-09-26 | 2017-09-26 | ウリジンヌクレオシド誘導体、組成物及び使用方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20200040025A1 (enExample) |
| EP (1) | EP3515447A4 (enExample) |
| JP (1) | JP7121731B2 (enExample) |
| CA (1) | CA3038519A1 (enExample) |
| WO (1) | WO2018058148A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7506473B2 (ja) * | 2019-12-20 | 2024-06-26 | ポッカサッポロフード＆ビバレッジ株式会社 | アミロイドβ蓄積抑制剤 |
| WO2021194959A1 (en) * | 2020-03-24 | 2021-09-30 | Gliaguard, Inc. | Treatment of eye disorders with uridine phosphate derivatives |
| EP4301744A1 (en) | 2021-08-10 | 2024-01-10 | AbbVie Inc. | Nicotinamide ripk1 inhibitors |
| WO2024118503A1 (en) | 2022-11-28 | 2024-06-06 | Hongene Biotech Corporation | Functionalized n-acetylgalactosamine analogs |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4724232A (en) * | 1985-03-16 | 1988-02-09 | Burroughs Wellcome Co. | Treatment of human viral infections |
| JPH0344379A (ja) | 1989-07-13 | 1991-02-26 | Yamasa Shoyu Co Ltd | Ｎ↑３―ピペラジノウラシル誘導体 |
| US5859014A (en) * | 1995-06-09 | 1999-01-12 | Syntex (U.S.A.) Inc. | Pyrimidinedione, pyrimidinetrione, triazinedione and tetrahydroquinazolinedione derivatives as α1 -adrenergic receptor antagonists |
| CN102083429B (zh) | 2008-04-24 | 2014-05-28 | 新联基因公司 | Ido抑制剂 |
| KR20110079197A (ko) * | 2009-12-31 | 2011-07-07 | 제일모직주식회사 | 유기광전소자용 화합물 및 이를 포함하는 유기광전소자 |
| CN103906745B (zh) | 2011-09-30 | 2017-08-25 | 塔夫斯大学 | 用于治疗神经变性疾病的尿苷二磷酸衍生物、组合物和方法 |
| JP6523958B2 (ja) | 2012-09-28 | 2019-06-05 | タフツ・ユニバーシティ | ウリジン二リン酸誘導体、プロドラッグ、組成物およびそれらの使用 |
| CN103232509B (zh) | 2013-05-14 | 2015-07-08 | 郑州大学 | 氟尿嘧啶类化合物、其制备方法及其应用 |
-
2017
- 2017-09-26 EP EP17854152.0A patent/EP3515447A4/en not_active Withdrawn
- 2017-09-26 CA CA3038519A patent/CA3038519A1/en not_active Abandoned
- 2017-09-26 US US16/336,898 patent/US20200040025A1/en not_active Abandoned
- 2017-09-26 WO PCT/US2017/053565 patent/WO2018058148A1/en not_active Ceased
- 2017-09-26 JP JP2019516442A patent/JP7121731B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2960598T3 (es) | Compuestos para el tratamiento de enfermedades y trastornos oftálmicos | |
| JP2016513668A5 (enExample) | ||
| RU2526201C2 (ru) | Способ лечения артрита | |
| RU2010116708A (ru) | Бициклическое производное гамма-аминокислоты | |
| CN102421427B (zh) | 用于治疗特定癌症的包含rdea119/bay869766的药物组合 | |
| WO2017035408A1 (en) | Compounds for treatment of immune and inflammatory disorders | |
| WO2017035418A1 (en) | Disubstituted compounds for treatment of immune and inflammatory disorders | |
| WO2017035351A1 (en) | Amino compounds for treatment of medical disorders | |
| KR20050085537A (ko) | 다양한 제약 용도를 위한 알파2델타 리간드 | |
| JP2021530513A5 (enExample) | ||
| JP2005538099A5 (enExample) | ||
| AU2019226587A1 (en) | Afibrotic compounds, devices, and uses thereof | |
| WO2015051327A1 (en) | Treating inflammation using llp2a-bisphosphonate conjugates and mesenchymal stem cells | |
| JP2015532289A5 (enExample) | ||
| US20100087436A1 (en) | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection | |
| JP2011207905A (ja) | 脳虚血疾患を予防及び治療する薬剤の製造におけるｌ−ブチルフタリドの使用 | |
| US20240122957A1 (en) | Use of nicotinamide mononucleotide (nmn) for the prevention and/or treatment of rheumatoid arthritis, and corresponding compositions | |
| MY195178A (en) | Composition for Treating Joint Disease and Kit Containing Same | |
| JP2019085404A (ja) | 脳腫瘍の治療のための医薬 | |
| JP2023553989A5 (enExample) | ||
| CN1151793C (zh) | 多发性骨髓瘤的骨病变治疗用医药组合物 | |
| WO2022184114A1 (zh) | 抗il-17抗体治疗自身免疫性疾病和炎症的方法 | |
| JP2023500352A (ja) | 移植片対宿主病を予防又は治療するための化合物 | |
| US20240269120A1 (en) | Method for Treating an Autoimmune and Inflammatory Disease | |
| RU2024136706A (ru) | Химические соединения |